Topic: Makya: Iktos technology platform for AI-driven de novo drug design and multi-parametric optimization

Recording Duration: 52:31

Webinar Start Time: Sept 13, 2022, 10 – 11 AM CET & 5 – 6 PM CET

Quentin Perron

Chief Scientific Officier & Co-founder, Iktos

Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having a potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specialized in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.

Sree Vadlamudi

Vice President, Head of Business Development EU and RoW, Iktos

As Vice President, Head of Business Development EU and RoW, Iktos AI, Sree leads strategic business development outreach, alliance management, marketing & communication activities. Sree has a successful track record in Strategic Business Development, Technology Commercialisation and Alliance Management positions with increasing responsibility in the bio-pharma industry. Sree is instrumental in securing and managing partnerships with biotechs and pharma as well as maximising the value of AI-based technology platforms and the growth of the business. Sree has also held senior research management positions at biotechs and virtual biotechs. Named author of multiple patents and publications, delivered numerous invited talks at international conferences. Sree holds PhD in Medicinal Chemistry, and MBA with merit from Lancaster Business School.